Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica.
about
Neuromyelitis optica pathogenesis and aquaporin 4Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidenceThe expanded spectrum of neuromyelitis optica: evidences for a new definition.Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Devic's syndrome in aquaporin-4 antibody negative patient. What we need to know …Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica.Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosisAn immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumabAQP4 autoantibody assay performance in clinical laboratory service.Treatment of neuromyelitis optica: current debate.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLANew insights into neuromyelitis opticaCentral Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional StudyComplement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disordersSerologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.Clinical usefulness of cell-based indirect immunofluorescence assay for the detection of aquaporin-4 antibodies in neuromyelitis optica spectrum disorderCerebral Cortex Involvement in Neuromyelitis Optica Spectrum DisorderLack of KIR4.1 autoantibodies in Japanese patients with MS and NMO.Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature.Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study.Use of rituximab in multiple sclerosis: current progress and future perspectives.Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.Complement-dependent and -independent aquaporin 4-antibody-mediated cytotoxicity in human astrocytes: Pathogenetic implications in neuromyelitis optica.Mercury chloride decreases the water permeability of aquaporin-4-reconstituted proteoliposomes.The single nucleotide polymorphism site of aquaporin-4 gene in patients with neuromyelitis optica.Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS.Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity.Multimodal characterization of gray matter alterations in neuromyelitis optica.Aquaporin-4 antibody in neuromyelitis optica: re-testing study in a large population from China.Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients.Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology.Pathological study of subacute autoimmune encephalopathy with anti-AQP4 antibodies in a pregnant woman.Differential effects of fingolimod on B-cell populations in multiple sclerosis.Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder.Association Between the Single Nucleotide Polymorphism and the Level of Aquaporin-4 Protein Expression in Han and Minority Chinese with Inflammatory Demyelinating Diseases of the Central Nervous System.Normal brain imaging accompanies neuroimmunologically justified, autoimmune encephalomyelitis.Diagnostik und Therapie der Neuromyelitis optica
P2860
Q21245240-18544087-BC13-4C66-ADE4-5F2FE79DB4DDQ26999061-330C166B-CDDF-44CC-9F95-6D83F73A2B23Q30573084-C68336DA-718E-4AC2-A202-D182A118226BQ30577078-26A03E63-5AB7-42F1-9D71-2D865269C365Q31130607-ACFFF7B4-4E05-434D-827B-63B40ACE9C2AQ33576962-0F0A9760-7CA3-4286-A555-A341CD82BFB3Q33611158-BDDC694F-D224-4542-83F8-590D93C5486DQ33895664-447DC331-2C98-4F79-8AD7-E67072E21E37Q34368662-BC117EE8-E49A-45C1-B8C0-11E237D6EC26Q34409070-5291A269-B919-4FAA-BF76-0FB30A6F1F92Q35052199-EE2AFF2E-2455-4EC3-920D-2A05ABACD336Q35101408-CD02A8CE-498B-41F4-B0E2-5277FEEC7DD9Q35539641-1BE79F48-DE09-4B31-A825-CADD74AE9038Q35722940-A0F8CB0B-D2E0-474F-8E9E-1F5CE22DD3DEQ35753620-AF5E1F85-8361-4524-B63F-5EBD3F817293Q35776490-843BFBC8-1BB5-4D2D-912A-FCE07D5AA39AQ36189702-68B232BA-0004-4E89-B8CF-99F599B40169Q36789538-DD24E4E6-15B4-4E82-82A0-9693F5C29412Q37123014-C6C4C6D9-9361-4102-963D-90272133D7EEQ38151920-79E89F32-5FF4-4D41-A3CE-7A3A2FB6838FQ39785941-BDEE2D63-B2D8-4C9E-808E-D82531E10B3EQ40053831-38205DAF-46AA-4CD2-89C9-7C2AEDAF35DEQ44001747-F6EBB7D6-30CF-48E5-8784-0150FF0C2A81Q44945605-2D303C56-239E-4B5B-A3A0-47C40D2888D8Q46826906-BAB93406-B49D-4EA5-B219-F03545BDD78EQ47159383-EC071EC8-72AC-461C-B188-C76F30A2EA4AQ47968702-EE202B59-3792-4D8C-9A70-B27166105051Q48100298-284B93A3-1125-483F-8F16-0BFDC338800DQ48180736-FE71E628-317A-478B-9340-8A760F558825Q48431866-E9EA7839-BD6F-4E34-A898-F0CBF1F5799DQ48489811-4A1BD086-EDA8-4446-BF55-A2A09721053FQ48654695-01F2456F-F3B6-4DE6-91E7-8974D9411916Q48906234-153B7316-E69A-41FD-9C67-F300508BA3FDQ50860736-764CD56D-1765-42E5-9AF7-C8A580697618Q51467860-843C90DD-6440-4F72-AA8A-FE6327C29824Q53536257-EE5ECA4B-232C-4612-8836-1D139BD7399DQ54986325-A37DCDCC-D803-44B9-9E99-D86B087FCAF2Q56986486-8F07D92A-50DD-47C8-890B-BAFC00AAEB81
P2860
Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Establishment of a new sensiti ...... ibody in neuromyelitis optica.
@en
Establishment of a new sensiti ...... ibody in neuromyelitis optica.
@nl
type
label
Establishment of a new sensiti ...... ibody in neuromyelitis optica.
@en
Establishment of a new sensiti ...... ibody in neuromyelitis optica.
@nl
prefLabel
Establishment of a new sensiti ...... ibody in neuromyelitis optica.
@en
Establishment of a new sensiti ...... ibody in neuromyelitis optica.
@nl
P2093
P356
P1476
Establishment of a new sensiti ...... ibody in neuromyelitis optica.
@en
P2093
Isabelle Miyazawa
Kazuo Fujihara
Masashi Nakamura
Shohei Watanabe
Tatsuro Misu
Toshiyuki Takahashi
Yasuto Itoyama
P304
P356
10.1620/TJEM.210.307
P577
2006-12-01T00:00:00Z